Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes
- PMID: 16804082
- DOI: 10.2337/db05-1672
Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes
Abstract
Type 2 diabetes is characterized by defects in insulin secretion and action and is preceded by impaired fasting glucose (IFG). The islet anatomy in IFG and type 2 diabetes reveals an approximately 50 and 65% deficit in beta-cell mass, with increased beta-cell apoptosis and islet amyloid derived from islet amyloid polypeptide (IAPP). Defects in insulin action include both hepatic and extrahepatic insulin resistance. The relationship between changes in beta-cell mass, beta-cell function, and insulin action leading to type 2 diabetes are unresolved, in part because it is not possible to measure beta-cell mass in vivo, and most available animal models do not recapitulate the islet pathology in type 2 diabetes. We evaluated the HIP rat, a human IAPP transgenic rat model that develops islet pathology comparable to humans with type 2 diabetes, at age 2 months (nondiabetic), 5 months (with IFG), and 10 months (with diabetes) to prospectively examine the relationship between changes in islet morphology versus insulin secretion and action. We report that increased beta-cell apoptosis and impaired first-phase insulin secretion precede the development of IFG, which coincides with an approximately 50% defect in beta-cell mass and onset of hepatic insulin resistance. Diabetes was characterized by approximately 70% deficit in beta-cell mass, progressive hepatic and extrahepatic insulin resistance, and hyperglucagonemia. We conclude that IAPP-induced beta-cell apoptosis causes defects in insulin secretion and beta-cell mass that lead first to hepatic insulin resistance and IFG and then to extrahepatic insulin resistance, hyperglucagonemia, and diabetes. We conclude that a specific beta-cell defect can recapitulate the metabolic phenotype of type 2 diabetes and note that insulin resistance in type 2 diabetes may at least in part be secondary to beta-cell failure.
Similar articles
-
High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes.Diabetes. 2007 Aug;56(8):2016-27. doi: 10.2337/db07-0197. Epub 2007 May 2. Diabetes. 2007. PMID: 17475933
-
Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice.Diabetes. 2007 May;56(5):1324-32. doi: 10.2337/db06-1579. Epub 2007 Mar 12. Diabetes. 2007. PMID: 17353506
-
Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus.Exp Biol Med (Maywood). 2007 Jun;232(6):772-9. Exp Biol Med (Maywood). 2007. PMID: 17526769
-
Islet amyloid polypeptide: mechanisms of amyloidogenesis in the pancreatic islets and potential roles in diabetes mellitus.Lab Invest. 1992 May;66(5):522-35. Lab Invest. 1992. PMID: 1573849 Review.
-
Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus.N Engl J Med. 1989 Aug 24;321(8):513-8. doi: 10.1056/NEJM198908243210806. N Engl J Med. 1989. PMID: 2668761 Review.
Cited by
-
Mechanisms of islet amyloidosis toxicity in type 2 diabetes.FEBS Lett. 2013 Apr 17;587(8):1119-27. doi: 10.1016/j.febslet.2013.01.017. Epub 2013 Jan 18. FEBS Lett. 2013. PMID: 23337872 Free PMC article. Review.
-
Catechol-containing compounds are a broad class of protein aggregation inhibitors: Redox state is a key determinant of the inhibitory activities.Pharmacol Res. 2022 Oct;184:106409. doi: 10.1016/j.phrs.2022.106409. Epub 2022 Aug 20. Pharmacol Res. 2022. PMID: 35995346 Free PMC article.
-
High plasma levels of islet amyloid polypeptide in young with new-onset of type 1 diabetes mellitus.PLoS One. 2014 Mar 26;9(3):e93053. doi: 10.1371/journal.pone.0093053. eCollection 2014. PLoS One. 2014. PMID: 24671002 Free PMC article.
-
Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.Endocr Rev. 2008 May;29(3):367-79. doi: 10.1210/er.2007-0031. Epub 2008 Feb 21. Endocr Rev. 2008. PMID: 18292465 Free PMC article. Review.
-
Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans.Diabetes. 2008 Jun;57(6):1584-94. doi: 10.2337/db07-1369. Epub 2008 Mar 11. Diabetes. 2008. PMID: 18334605 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical